Nature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03630-w
In the OptiTROP-Breast01 phase 3 trial, patients with metastatic triple-negative breast cancer who received the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan experienced longer progression-free survival than patients treated with chemotherapy.
